Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 17:15:375-383.
doi: 10.2147/PHMT.S489512. eCollection 2024.

Utilizing T-Lymphocyte Activation-Related Cytokines to Predict Non-Responsiveness to Treatment in Pediatric Kawasaki Disease

Bei Ye  1 , Jiying Xiao  2 , Caiyun Zhang  3
Affiliations

Utilizing T-Lymphocyte Activation-Related Cytokines to Predict Non-Responsiveness to Treatment in Pediatric Kawasaki Disease

Bei Ye et al. Pediatric Health Med Ther. .

Abstract

Objective: To investigate the predictive value of T-lymphocyte activation-related cytokines in non-responsive Kawasaki disease.

Methods: Eighty-two children with Kawasaki disease, hospitalized from June 2022 to December 2023, were divided into two groups based on treatment response: the sensitive Kawasaki disease group (n=71) and the non-responsive Kawasaki disease group (n=11). Serum levels of T-lymph activation-related cytokines, including interleukin-2, 6, 7, 12, 15, 17, and tumor necrosis factor alpha, were measured before and after IVIG treatment in both groups. The differences in cytokine levels between the two groups were compared pre- and post-treatment. The ability of these cytokines to discriminate non-responsive Kawasaki disease was evaluated using ROC curves to determine the cut-off value.

Results: Before initial treatment, IL-2, IL-6, IL-7, IL-12, IL-15, IL-17, and tumor necrosis factor-α values were significantly higher in the non-responsive Kawasaki disease group compared to the sensitive Kawasaki disease group. Comparisons before and after initial treatment showed significant decreases in IL-6 and 17 in the sensitive Kawasaki disease group and significant decreases in IL-6 and 7 in the non-responsive Kawasaki disease group. IL-6 and 17 significantly increased in the sensitive group compared to the non-responsive group after initial treatment. The ROC curves indicated that IL-6 predicted the area under the curve (AUC) for non-responsive Kawasaki disease to be 0.859 before treatment and 0.920 after treatment. Similarly, IL-17 had AUC values of 0.699 before treatment and 0.884 after treatment.

Conclusion: Reassessing IL-6 and IL-17 following the initial treatment for Kawasaki disease may improve early warning signals for unresponsive Kawasaki disease.

Keywords: Kawasaki disease; T-lymphocyte activation; cytokines; immunoglobulin; unresponsive Kawasaki disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted without any commercial or financial relationships that might be interpreted as potential conflicts of interest.

Figures

Figure 1
Figure 1
The study assessed the variations in cytokine levels associated with T lymphocyte activation (IL-2, 6, 7, 12, 15, 17, and TNF-α) across different groups. (A) Significant differences in IL-2 levels were noted between the sensitive and non-responsive groups, both before and after treatment (P < 0.05). (B) Statistically significant differences in IL-6 levels were observed in the sensitive group compared to the non-reactive group before and after treatment, as well as within each group over the treatment period (P < 0.05). (C) Statistically significant differences were observed pre-treatment between the sensitive and non-responsive groups, and within the non-responsive group before and after treatment (P < 0.05). (D) There was a significant difference in IL-12 levels between the sensitive and non-responsive groups before treatment (P < 0.05). (E) Statistically significant differences were noted between the IL-15-sensitive and non-responsive groups before and after treatment (P < 0.05). (F) Significant variations in IL-17 levels were noted between the sensitive and non-responsive groups before and after treatment, including changes within the sensitive group itself (P < 0.05). (G) A significant difference in TNF-α levels was found between the sensitive and non-responsive groups before treatment (P < 0.05).
Figure 2
Figure 2
The ROC curves illustrate the pre- and post-treatment area under the curve for IL-6 and IL-17 in predicting nonresponsive Kawasaki disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Piram M, Darce Bello M, Tellier S, et al. Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease. Sci Rep. 2020;10(1):3125. doi:10.1038/s41598-020-59972-7 - DOI - PMC - PubMed
    1. Chen J, Liao J, Xiang L, et al. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review. Front Immunol. 2023;14:1237670. doi:10.3389/fimmu.2023.1237670 - DOI - PMC - PubMed
    1. Han SB, Lee SY. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches. World J Pediatr. 2020;16(6):566–574. doi:10.1007/s12519-020-00360-6 - DOI - PubMed
    1. Friedman KG, Jone PN. Update on the management of Kawasaki disease. Pediatr Clin North Am. 2020;67(5):811–819. doi:10.1016/j.pcl.2020.06.002 - DOI - PubMed
    1. Takekoshi N, Kitano N, Takeuchi T, et al. Analysis of age, sex, lack of response to intravenous immunoglobulin, and development of coronary artery abnormalities in children with Kawasaki disease in Japan. JAMA Netw Open. 2022;5(6):e2216642. doi:10.1001/jamanetworkopen.2022.16642 - DOI - PMC - PubMed

LinkOut - more resources